405 related articles for article (PubMed ID: 23122646)
21. [Rivaroxaban in the prevention and treatment of thromboembolic disorders].
Helbing T; Bode C; Moser M
Hamostaseologie; 2012; 32(3):195-202. PubMed ID: 22777255
[TBL] [Abstract][Full Text] [Related]
22. Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor.
Biemond BJ; Perzborn E; Friederich PW; Levi M; Buetehorn U; Büller HR
Thromb Haemost; 2007 Mar; 97(3):471-7. PubMed ID: 17334516
[TBL] [Abstract][Full Text] [Related]
23. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis.
Bamber L; Wang MY; Prins MH; Ciniglio C; Bauersachs R; Lensing AW; Cano SJ
Thromb Haemost; 2013 Oct; 110(4):732-41. PubMed ID: 23846019
[TBL] [Abstract][Full Text] [Related]
24. Treatment of patients with acute deep vein thrombosis and/or pulmonary embolism: efficacy and safety of non-VKA oral anticoagulants in selected populations.
Prandoni P
Thromb Res; 2014 Aug; 134(2):227-33. PubMed ID: 24875390
[TBL] [Abstract][Full Text] [Related]
25. Rivaroxaban for the treatment of pulmonary embolism.
Vanassche T; Verhamme P
Adv Ther; 2013 Jun; 30(6):589-606. PubMed ID: 23807375
[TBL] [Abstract][Full Text] [Related]
26. Oral rivaroxaban for symptomatic venous thromboembolism.
Landman GW; Gans RO
N Engl J Med; 2011 Mar; 364(12):1178; author reply 1178. PubMed ID: 21428778
[No Abstract] [Full Text] [Related]
27. Novel oral anticoagulants in development: Dabigatran, Rivaroxaban, and Apixaban.
Sattari M; Lowenthal DT
Am J Ther; 2011 Jul; 18(4):332-8. PubMed ID: 20535013
[TBL] [Abstract][Full Text] [Related]
28. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.
Stevenson M; Scope A; Holmes M; Rees A; Kaltenthaler E
Health Technol Assess; 2009 Oct; 13 Suppl 3():43-8. PubMed ID: 19846028
[TBL] [Abstract][Full Text] [Related]
29. The potential of target-specific oral anticoagulants for the acute and long-term treatment of venous thromboembolism.
Akwaa F; Spyropoulos AC
Curr Med Res Opin; 2014 Nov; 30(11):2179-90. PubMed ID: 25105309
[TBL] [Abstract][Full Text] [Related]
30. Review of an article: oral rivaroxaban for symptomatic venous thromboembolism. The EINSTEIN Investigators et al. N Engl J Med 2010; 363(26):2499-2510.
Nunnelee JD
J Vasc Nurs; 2011 Jun; 29(2):89. PubMed ID: 21558032
[No Abstract] [Full Text] [Related]
31. Rivaroxaban (Xarelto)--a new oral anticoagulant.
Med Lett Drugs Ther; 2011 Aug; 53(1371):65-7. PubMed ID: 21860366
[No Abstract] [Full Text] [Related]
32. Dose-escalation study of rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--for the prevention of venous thromboembolism in patients undergoing total hip replacement.
Eriksson BI; Borris LC; Dahl OE; Haas S; Huisman MV; Kakkar AK; Misselwitz F; Muehlhofer E; Kälebo P
Thromb Res; 2007; 120(5):685-93. PubMed ID: 17292948
[TBL] [Abstract][Full Text] [Related]
33. [Advances in venous thromboembolism].
Qin L; Lu WX
Zhonghua Jie He He Hu Xi Za Zhi; 2013 May; 36(5):372-4. PubMed ID: 24047815
[No Abstract] [Full Text] [Related]
34. FDA approves rivaroxaban for prevention of deep-vein thrombosis in surgery.
Aalbers J
Cardiovasc J Afr; 2011; 22(4):218. PubMed ID: 21881694
[No Abstract] [Full Text] [Related]
35. Anticoagulation with rivaroxaban: covering a broad spectrum of thromboembolic disease.
Schellong S
Expert Rev Cardiovasc Ther; 2013 Jul; 11(7):817-28. PubMed ID: 23895025
[TBL] [Abstract][Full Text] [Related]
36. Clinical management of rivaroxaban-treated patients.
Palareti G; Ageno W; Ferrari A; Filippi A; Imberti D; Pengo V; Rubboli A; Toni D
Expert Opin Pharmacother; 2013 Apr; 14(5):655-67. PubMed ID: 23414291
[TBL] [Abstract][Full Text] [Related]
37. Rivaroxaban for the treatment of venous thromboembolism. A "real-life" perspective in 103 patients.
Jara-Palomares L; Sanchez-Oro-Gomez R; Elias-Hernandez T; Morillo-Guerrero R; Ferrer-Galvan M; Asensio-Cruz MI; Barrot-Cortes E; Otero-Candelera R
Thromb Res; 2014 Sep; 134(3):617-21. PubMed ID: 25034320
[TBL] [Abstract][Full Text] [Related]
38. The risk of recurrent thromboembolic disorders in patients with unprovoked venous thromboembolism: new scenarios and opportunities.
Prandoni P; Barbar S; Milan M; Vedovetto V; Pesavento R
Eur J Intern Med; 2014 Jan; 25(1):25-30. PubMed ID: 24120221
[TBL] [Abstract][Full Text] [Related]
39. Rivaroxaban: a novel, oral, direct factor Xa inhibitor.
Abrams PJ; Emerson CR
Pharmacotherapy; 2009 Feb; 29(2):167-81. PubMed ID: 19170587
[TBL] [Abstract][Full Text] [Related]
40. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement.
Eriksson BI; Borris LC; Dahl OE; Haas S; Huisman MV; Kakkar AK; Muehlhofer E; Dierig C; Misselwitz F; Kälebo P;
Circulation; 2006 Nov; 114(22):2374-81. PubMed ID: 17116766
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
